Adalvo announces the successful launch of Rivaroxaban Film-Coated Tablets in the United Kingdom.
Developed based on the reference brand Xarelto, Rivaroxaban is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) or with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD).
As a blockbuster product, Rivaroxaban has made a substantial impact on the global pharmaceutical market.
According to IQVIA, the total global MAT sales for Rivaroxaban in 2023 amounted to approximately $13.3 billion, with a 3Y CAGR of 2%.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!